Olan

Quick links to important sections

Olan

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olan

Quick Facts: Olan Identity

Property Description
Active ingredient Olanzapine
Form Tablet, Orally Disintegrating Tablet (ODT), Powder for Intramuscular Injection
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
General Purpose Stabilizing key brain chemical activity
Origin Synthetic (Thienobenzodiazepine chemical class)

What Type of Medicine is Olan (Olanzapine)?

Olan is a synthetic, prescription-only medication whose active ingredient is Olanzapine. It is classified as an atypical antipsychotic, falling under the broader group of psychotropic agents that specifically target the central nervous system. The compound is chemically derived from the thienobenzodiazepine class. This classification establishes its role as a key second-generation agent distinguished by its comprehensive receptor profile.

Olanzapine is known for its effectiveness in stabilizing emotional and thought processes. It is a single-ingredient product (monotherapy), focusing its entire therapeutic action on the properties of Olanzapine, and is strictly accessible only through a prescription.


Composition and Available Forms of Olan

The core composition of Olan is the active substance Olanzapine. This ingredient is formulated into several distinct dosage forms, providing flexibility for patient compliance and specific clinical needs: a standard oral tablet, an orally disintegrating tablet (ODT), and a powder for intramuscular injection.

The distinction between the ODT and the standard tablet represents a key differentiating feature, as the ODT dissolves rapidly on the tongue without water. The injectable form is often clinically recognized for providing rapid stabilization. These forms determine the initial route of administration: oral or intramuscular. All formulations consist of the active Olanzapine combined with necessary pharmaceutical excipients or diluents.


General Purpose: How Olan Helps Stabilize Brain Activity

The general purpose of Olan is to promote stabilization within the brain’s neurochemical signaling pathways. It accomplishes this by functioning as a multireceptor antagonist that regulates the activity of two principal chemical messengers: dopamine and serotonin. Olanzapine binds to multiple receptors, supporting its function as a broad-acting central nervous system stabilizer.

By modulating the effect of dopamine and serotonin, Olanzapine acts to stabilize communication between nerve cells. This comprehensive chemical rebalancing is the fundamental, high-level function of the drug. Its role is to help mitigate and regulate significant disturbances in thought, mood, and perception that result from an underlying neurochemical imbalance, thereby facilitating a more stable neurological state.

What side effects are possible with Olan?

Official Safety Profile and Adverse Reactions

The official safety profile of Olanzapine (Olan) is structured by regulatory bodies to categorize possible adverse reactions by the physiological system affected and their reported frequency. Side effects are classified based on incidence observed in clinical trials.

Frequency Classification Examples of Documented Adverse Reactions
Very Common (May affect more than 1 in 10 people) Weight gain, Somnolence (sleepiness), Increased appetite, Elevated prolactin, cholesterol, and glucose levels.
Common (May affect up to 1 in 10 people) Dizziness, Orthostatic hypotension, Akathisia, Parkinsonism, Constipation, Dry mouth, Asthenia, and transient elevations of liver enzymes.

Serious adverse reactions are specifically highlighted in official labeling. These include the risk of Neuroleptic Malignant Syndrome (NMS), severe Hyperglycemia (potentially leading to ketoacidosis or coma), and the development of Tardive Dyskinesia, which involves involuntary movements.

Safety Constraints and Special Populations

Regulatory documents include specific safety constraints. Olanzapine is associated with the potential to impair judgment, thinking, and motor skills, and may affect the body's ability to regulate temperature. Orthostatic hypotension is noted as a risk, particularly during the initial phase of treatment.

Specific populations have documented safety considerations: The medication is not approved for elderly patients with dementia-related psychosis due to a documented increased risk of death and cerebrovascular events. Adolescents are reported to experience a greater magnitude of weight gain and prolactin elevation compared to adults.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Olanzapine details specific clinical signs and outcomes associated with an overdose, strictly dictating when emergency medical attention must be sought.

Overdose Presentation and Outcomes
Documented Manifestations: CNS depression, including drowsiness, slurred speech (dysarthria), and a reduced level of consciousness ranging to coma. Cardiovascular signs include tachycardia and hypotension. Other effects documented are extrapyramidal symptoms (EPS), seizures, and respiratory depression.
Severe Outcomes: Life-threatening events officially associated with overdose include cardiopulmonary arrest and reports of fatality. The presentation may also be consistent with Neuroleptic Malignant Syndrome (NMS).
Immediate Action Required: Individuals must seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if the affected person has collapsed, is seizing, or cannot be awakened.

Management and Monitoring

No specific antidote is known; therefore, treatment is officially defined as symptomatic and supportive. Required medical procedures focus on maintaining a patent airway, ensuring adequate oxygenation and ventilation, and providing close medical supervision until all clinical signs have resolved.

Population Considerations

Specific consideration is noted for children, who may experience more significant adverse effects requiring active intervention. Regulatory warnings also note the increased risk of death in elderly patients with dementia-related psychosis treated with antipsychotic drugs, which remains a critical factor in overdose scenarios.

Therapeutic Uses of Olan

What Olan Treats: Main Uses and Benefits

The core therapeutic uses of Olanzapine cover severe mental health conditions and their related acute symptomatic episodes. The medication is indicated for Schizophrenia and Bipolar I Disorder, including acute manic/mixed episodes, and is used in combination regimens for depressive episodes of Bipolar I and treatment-resistant depression.


Symptomatic Support and Stabilization

This medication is applied across domains where additional symptomatic support is needed, primarily for conditions presenting with acute or disruptive symptom patterns. It helps address symptom clusters that may become intense or disruptive, such as the hallucinations and disorganized thinking associated with psychosis, and the extreme mood swings of manic or mixed episodes. Olan plays a role in managing these acute states, often applied during phases of increased distress or discomfort when symptoms become temporarily overwhelming.

The medication's primary benefit is that it assists with supporting a sense of stability by easing the overall burden of core symptoms and contributing to easing the overall symptom load associated with episodic manifestations.

“The aim is to support patients in coping more steadily with difficult episodes and contribute to their general well-being during symptomatic phases.”


Quick Fact: Relief for Key Symptom Clusters
Psychosis: Plays a role in easing delusions, hallucinations, and disorganized thinking.
Mania: Assists with managing elevated mood, irritability, and hyperactivity.
Acute Agitation: Used when short-term symptomatic assistance is needed during behavioral crises.

Regulatory References

  1. NIH National Library of Medicine (NCBI) StatPearls overview

Eligibility and Restrictions for Use

The eligibility for Olan (Olanzapine) is defined by official regulatory documentation, primarily based on age, pre-existing conditions, and physiological status.

Populations Excluded or Not Recommended

Classification Population or Condition
Contraindicated Patients with known hypersensitivity to Olanzapine or any component.
Not Recommended Elderly patients with dementia-related psychosis (due to increased mortality risk).
Use Not Established Children younger than 13 years of age for monotherapy.

Populations Requiring Conditional Use

Official labeling requires caution in several populations:

  • Organ Impairment: Patients with hepatic impairment or those with factors leading to slowed drug metabolism (e.g., non-smoking, older adults) require special consideration.
  • Comorbidities: Caution is necessary in patients with a history of seizures or conditions susceptible to anticholergic effects, such as narrow-angle glaucoma or prostatic hypertrophy.
  • Reproductive Status: Use during pregnancy is limited to situations where the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended by the manufacturer.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation identifies specific patterns where Olan (Olanzapine) interacts with other substances, primarily affecting drug concentrations (pharmacokinetics) or central nervous system effects (pharmacodynamics).

Documented Interaction Patterns

Category Interacting Agents / Products Official Regulatory Description
Metabolic Inhibition (Increased Levels) Fluvoxamine Significantly increases Olanzapine plasma concentrations by inhibiting CYP1A2 enzyme activity.
Metabolic Induction (Reduced Levels) Carbamazepine, Smoking Increases Olanzapine clearance, leading to reduced plasma concentrations via CYP1A2 induction.
Pharmacodynamic Enhancement Alcohol, Other CNS Depressants May cause additive effects, increasing the risk of sedation and central nervous system depression.
Hypotension/Sedation Risk Parenteral Benzodiazepines Concomitant injection with intramuscular Olanzapine is not recommended due to increased risk of excessive sedation and orthostatic hypotension.
Antagonism Levodopa, Dopamine Agonists Olanzapine may reduce the effectiveness of these agents due to its dopamine receptor antagonism.

Population and General Considerations

The absorption of oral Olanzapine is not affected by food. Caution is officially advised for patients with hepatic impairment when co-administering potentially hepatotoxic medicines. Furthermore, regulatory documents note that Olanzapine clearance is affected by both gender and smoking status, which is relevant when considering other exposure-altering interactions.

Mechanism of Action

Targeted Modulation of Neurotransmitter Receptors

Olan's primary pharmacodynamic action involves binding as an antagonist to specific dopamine and serotonin receptor subtypes in the central nervous system (CNS). The agent exhibits high affinity for multiple sites, including the D2 dopamine and 5- HT2 A serotonin receptors. This receptor occupation prevents the natural neurotransmitters from activating these sites, thereby initiating changes in neuronal activity patterns.


Influence on Intracellular Signaling Cascades

The receptor antagonism modifies the subsequent intracellular signal transduction cascades within the nerve cell. This mechanism alters the activity of second messenger systems and downstream regulatory proteins, consequently adjusting the propagation of molecular signals across affected neuronal circuits. The modification of these early molecular steps influences the cell's responsiveness to continuous input.


️ Mechanistic Regulation of Physiological Activity

The cumulative effect of receptor modulation and cascade influence results in an adjustment of activity within specific CNS physiological processes. This activity modifies the downstream cellular response to excessive mediator activity and influences the resulting physiological effects by engaging regulatory mechanisms within the affected pathways. This action contributes to establishing a more balanced baseline functional state.

Dosage and Administration Information

How Olan is Used

Administration of Olan, which contains the active ingredient Olanzapine, is guided by distinct protocols. The medication is available in multiple forms, defining two primary routes of administration: oral (tablet and orally disintegrating tablet/ODT) and intramuscular (IM) injection.


Dosing and Frequency Patterns

Usage Context Typical Adult Dosing Range Standard Frequency
Oral Maintenance (Schizophrenia/Bipolar) 5 mg to 20 mg daily Once Daily
IM Acute Agitation (Short-Acting) Initial dose typically 10 mg Can be repeated, max 30 mg in 24 hours

Oral forms are typically taken once daily and may be administered without regard to meals. The IM injection is strictly for short-term, acute use and must not be administered intravenously or subcutaneously; it is often given in a supervised setting for acute control. The long-acting IM form is used for maintenance and is typically administered by a healthcare professional on a bi-weekly or monthly schedule.


Procedural and Population Adjustments

The dosage initiation often requires titration, meaning the dose is adjusted gradually over time, usually in increments of 5 mg, with changes occurring no more frequently than once every 24 hours. Specific population adjustments are required: a lower starting dose (e.g., 5 mg) should be considered for older adults and individuals with known hepatic or renal impairment to align with standardized protocols. Additionally, the ODT formulation must be handled with dry hands and allowed to dissolve on the tongue for proper intake, while the short-acting IM powder requires reconstitution immediately before use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Olan (Olanzapine)

The clinical evaluation of Olan has involved extensive clinical trials, primarily randomized controlled trials (RCTs) and long-term observational studies, which form the basis of research into the medicine for its approved uses. The body of evidence focuses on conditions characterized by fluctuating or episodic manifestations, such as schizophrenia and bipolar I disorder.


Evidence for Use in Schizophrenia

Research has explored Olan in studies involving periods of heightened symptoms, using both oral tablet and long-acting injection (LAI) formulations.

What Researchers Studied and Reported Studies used in research exploring how symptoms change over time have included short-term RCTs that typically lasted between four and eight weeks. These trials focused on adults and some adolescent populations experiencing acute flare-ups. Outcomes were measured using standardized scales, such as the PANSS (Positive and Negative Syndrome Scale), to monitor the intensity and variability of symptoms like hallucinations and disorganized thinking. Findings describe patterns observed in the studies related to the change in measurements of these acute symptoms compared to inactive controls. Longer-term studies, some extending for several years, were conducted to monitor sustained stability and outcomes related to recurrence. These studies collected data on how patients reported their experience over extended maintenance periods.

What Remains Uncertain While research provides insight into short-term changes during the acute phase, the evidence is limited by the relatively short follow-up durations of the primary controlled trials. High patient dropout rates in these trials mean that long-term effects are not fully established based on the gold standard of controlled evidence. Data for certain groups, such as those with a first-episode of psychosis, remain insufficient for drawing broad conclusions.


Evidence for Use in Bipolar I Disorder: Acute Episodes

Olan was studied for research contexts involving fluctuating or unstable symptoms linked to acute manic or mixed episodes of Bipolar I Disorder.

What Researchers Studied and Reported Studies for acute mania were conducted during periods of increased symptom activity and were typically short-term RCTs lasting approximately three to four weeks. Research examined outcomes reflecting daily functioning or activity level, primarily by monitoring the change in manic symptom severity using tools like the YMRS (Young Mania Rating Scale). Findings describe patterns observed in the studies related to the measured change in symptom severity. Trials for the intramuscular injection formulation specifically monitored responses over defined time intervals to assess its use in episodes where symptoms become more noticeable.

What Remains Uncertain The primary evidence is restricted to the very short-term (3–4 week) acute stabilization period, offering limited insight into intermediate- or long-term management. Interpretation is limited by the fact that many trials lacked a robust active comparator arm. The certainty of the findings should be viewed within the context of these modest sample sizes and short follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Olan (FAQ)

Q: How quickly should a person expect to feel the effects of Olan?

Initial therapeutic effects for managing acute symptoms, such as acute agitation, may be observed quickly, sometimes within 15 minutes following an injection. For oral formulations used in conditions like schizophrenia or bipolar mania, noticeable changes typically begin within days to one or two weeks, with continued stabilization often occurring over four to six weeks. Official information indicates that the full benefit is usually achieved after a period of ongoing treatment.

Q: Are there ways to manage or prevent weight gain while taking Olan?

Since weight gain is a documented and common side effect, official sources often mention approaches to help manage it. Approaches often mentioned in documentation to address weight gain include maintaining a balanced diet and incorporating regular physical activity. These lifestyle adjustments are intended to help keep a person’s weight stable while taking the medication.

Q: Does Olan cause long-term side effects that I should know about?

Studies and official information indicate that long-term use is associated with potential risks that require regular monitoring. These include changes to a person’s metabolic profile, such as high blood sugar and elevated cholesterol levels. There is also a risk of movement disorders, such as tardive dyskinesia, which involves involuntary movements and may persist even if the medicine is stopped.

Q: What kind of monitoring (like blood tests) is required while on Olan?

Official product information suggests that regular monitoring is typically required due to the potential for metabolic changes. This usually involves checking blood sugar (glucose) and blood lipid (cholesterol) levels before starting treatment and periodically throughout the course of treatment. This monitoring is done to identify changes early.

Q: Is Olan safe for older adults or elderly patients?

Official safety warnings clearly state that Olan is not approved for use in elderly patients with dementia-related psychosis because of a documented increased risk of death. For older adults without this condition, standardized protocols indicate that a lower starting amount may be considered by a healthcare provider.

Q: Is Olan treatment a lifelong commitment, or can it be stopped eventually?

The duration of treatment is determined by a healthcare provider based on the individual’s specific condition and response. The medication is typically not stopped suddenly, according to documentation; if discontinuation is planned, the dosage may be slowly lowered over time to allow the body to adjust.

Q: What happens if a person forgets to take a dose of Olan?

Official documentation provides guidance for managing a missed amount of Olan. This usually involves descriptive instructions detailing when to take a missed amount and when to skip it to avoid taking excessive amounts close together. These actions are described to maintain the regular schedule without doubling.

Q: Why does Olan sometimes cause restlessness or an urge to move (akathisia)?

Restlessness or an urge to move, known as akathisia, is a common side effect of Olan. While the exact reason is not fully understood, this effect is related to the way the drug interacts with and blocks specific dopamine receptors in the brain. This is a mechanism seen with various medications in this pharmacological class.

Q: Does Olan affect body temperature or make a person more sensitive to heat?

Official warnings state that Olan may affect the body’s ability to regulate its core temperature. Official documentation notes a risk of overheating; therefore, caution regarding vigorous activity in hot environments and maintaining hydration levels is often mentioned.

Q: Is it correct that Olan is only used for serious mental health conditions?

Olan is approved by regulatory agencies to treat several specific conditions. These include schizophrenia and manic or mixed episodes associated with bipolar I disorder. It is also approved for use in combination with fluoxetine to treat depressive episodes of bipolar I disorder and treatment-resistant depression.

Q: Does Olan cause high blood pressure?

Official safety profiles indicate that Olan is commonly associated with orthostatic hypotension, which is a drop in blood pressure that occurs when a person stands up too quickly. High blood pressure, or hypertension, is not listed as a common or primary safety warning in the official documentation.

Q: Does Olan affect memory or concentration in the long term?

Official prescribing information notes that the medication can temporarily impair judgment, thinking, and motor skills, particularly when starting treatment. However, regulatory documents do not explicitly detail the effects of Olan on memory or concentration over the long term.

Q: Are there any specific foods to avoid while taking Olan?

According to the official product information, the absorption of the oral form of Olan is not affected by food. Therefore, there are generally no specific food groups or items that are officially recommended to be avoided.

Q: Does Olan affect the liver or kidneys?

Official documents note that Olan is associated with transient elevations of liver enzymes. Caution is advised for patients with existing liver problems, and a lower starting dose may be considered for those with hepatic impairment. The medication’s elimination is less reliant on the kidneys, and renal dysfunction alone is not noted as a major concern.

Q: Can taking Olan cause changes in my menstrual cycle?

A possible side effect listed in official safety documents is elevated prolactin levels. High prolactin is a known factor that can be associated with changes in a person’s menstrual cycle.

Q: Why is Olan sometimes prescribed for conditions other than its main use?

Olan is approved to treat specific symptoms and disorders. Approved uses include schizophrenia, manic or mixed episodes of bipolar I disorder, and depressive episodes of bipolar I disorder or treatment-resistant depression when used in combination with fluoxetine.

Q: Is it safe to drink alcohol in moderation while on Olan?

Official warnings state that the use of alcohol while taking Olan should be avoided or limited. Combining the two can increase nervous system side effects such as dizziness, drowsiness, and difficulty concentrating due to additive effects.

Q: Does Olan interact negatively with caffeine or nicotine/smoking?

Official product information notes that cigarette smoking can increase the clearance of Olan from the body. This may mean that a higher amount of the medication is required to maintain the desired effect. Regulatory labels do not mention a direct interaction with caffeine.

Q: Does Olan interact with common over-the-counter medicines like ibuprofen or cold remedies?

Regulatory documents advise caution when combining Olan with any other medicine that affects the central nervous system (the brain). This includes certain sedatives or sedating antihistamines, which are common ingredients in some cold remedies, as combining them can worsen side effects like drowsiness.

Q: Is there a different level of effectiveness between the brand-name and generic versions of Olan?

According to the official regulatory statement of bioequivalence, the generic versions of Olan tablets and orally disintegrating tablets are considered to contain the same active ingredient and work in the same way as the brand-name product. This means they are expected to have the same effectiveness.

Q: Can Olan be taken by teenagers or children?

Olan is approved for use in young people for certain conditions. It is approved for schizophrenia and bipolar I disorder in adolescents aged 13 to 17 years. When used in combination with fluoxetine, it is approved for children 10 to 17 years of age for depressive episodes of bipolar I disorder.

Q: Does Olan affect sexual function or libido?

Official safety profiles list changes in sexual function, including a change in sex drive or performance, among the potential side effects. These effects are often associated with the medication's potential to cause high prolactin levels.

Q: Can Olan interact with recreational substances like cannabis (CBD/THC)?

Official warnings state that caution should be exercised regarding the use of marijuana or other forms of cannabis while taking Olan. This is because these substances may have additive effects that can lead to increased sedation and slow a person's physical and mental actions.

How should Olan be stored and disposed of?

Storage and Environmental Control

Olan (olanzapine) tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and stored away from excess heat, moisture, and freezing environments. The medication must be secured out of the sight and reach of children, with locked safety caps used to prevent accidental exposure.

Packaging and Stability Constraints

Orally Disintegrating Tablets (ODT) must remain in their sealed package until the moment of administration and should be used immediately after opening. Powder for intramuscular injection, once reconstituted, must also be used within 1 hour. These requirements preserve the product's defined stability profile.

Official Disposal Instructions

Expired or unused Olan should be disposed of in accordance with local requirements, with a medicine take-back program being the preferred method. If a take-back program is unavailable, do not flush the medication. Instead, mix it with an undesirable substance, place it in a sealed container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olan found in:

A-Z Index: